Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Key Launches Ahead But Vifor Plots More Pipeline Deals

Solid 2020 In Spite Of COVID-19 Impact

Executive Summary

Stefan Schulze, CEO of the Swiss iron deficiency and kidney disease specialist, tells Scrip that Vifor's reputation as a go-to industry partner should result in at least two more licensing deals or product acquisitions in 2021.

You may also be interested in...



Deal Watch: AI Specialist Biolojic Inks Diabetes Pact With Lilly, Autoimmune Tie-Up With Nektar

Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.

EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data

Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.

Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel